Veterinary Medicines

Vanguard 7

Not authorised
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain Snyder Hill, Live
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
  • Leptospira interrogans, serovar Canicola, strain C51, Inactivated
  • Canine parvovirus, strain NL-35-D, Live
Download as PDF

Product identification

Medicine name:
Vanguard 7
Active substance:
  • Canine parainfluenza virus, strain NL-CPI-5, Live
  • Canine adenovirus 2, strain Manhattan, Live
  • Canine distemper virus, strain Snyder Hill, Live
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
  • Leptospira interrogans, serovar Canicola, strain C51, Inactivated
  • Canine parvovirus, strain NL-35-D, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Canine parainfluenza virus, strain NL-CPI-5, Live
    1000000.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine adenovirus 2, strain Manhattan, Live
    1585.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
  • Canine distemper virus, strain Snyder Hill, Live
    1000.00
    50% tissue culture infectious dose
    /
    1.00
    Dose
  • Leptospira interrogans, serovar Icterohaemorrhagiae, strain NADL 11403, Inactivated
    40.00
    Hamster protective Dose 80%
    /
    1.00
    millilitre(s)
  • Leptospira interrogans, serovar Canicola, strain C51, Inactivated
    40.00
    Hamster protective Dose 80%
    /
    1.00
    millilitre(s)
  • Canine parvovirus, strain NL-35-D, Live
    10000000.00
    50% tissue culture infectious dose
    /
    1.00
    millilitre(s)
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AI02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Surrendered
Authorised in:
  • Germany
Package description:

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Immunological veterinary medicinal product application (Article 13d of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Zoetis Deutschland GmbH
Marketing authorisation date:
Manufacturing sites for batch release:
  • Zoetis Belgium
Responsible authority:
  • Paul-Ehrlich-Institut
Authorisation number:
  • 8a/91
Date of authorisation status change:

Documents

Summary of Product Characteristics

English (PDF)
Published on: 12/01/2023
Download
German (PDF)
Published on: 12/01/2023
Download